BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Reese PP, Abt PL, Blumberg EA, Van Deerlin VM, Bloom RD, Potluri VS, Levine M, Porrett P, Sawinski D, Nazarian SM, Naji A, Hasz R, Suplee L, Trofe-Clark J, Sicilia A, McCauley M, Gentile C, Smith J, Niknam BA, Bleicher M, Reddy KR, Goldberg DS. Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial. Ann Intern Med. 2018;169:273-281. [PMID: 30083748 DOI: 10.7326/m18-0749] [Cited by in Crossref: 124] [Cited by in F6Publishing: 44] [Article Influence: 31.0] [Reference Citation Analysis]
Number Citing Articles
1 Sawinski D, Forde KA, Lo Re V 3rd, Goldberg DS, Cohen JB, Locke JE, Bloom RD, Brensinger C, Weldon J, Shults J, Reese PP. Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study. Am J Kidney Dis 2019;73:815-26. [PMID: 30704882 DOI: 10.1053/j.ajkd.2018.11.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
2 Dahlqvist G, Moreno C, Starkel P, Detry O, Coubeau L, Jochmans I. Innovations in liver transplantation in 2020, position of the Belgian Liver Intestine Advisory Committee (BeLIAC). Acta Gastroenterol Belg 2021;84:347-59. [PMID: 34217187 DOI: 10.51821/84.2.347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Boyarsky BJ, Strauss AT, Segev DL. Transplanting Organs from Donors with HIV or Hepatitis C: The Viral Frontier. World J Surg 2021. [PMID: 33471156 DOI: 10.1007/s00268-020-05924-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sise ME, Goldberg DS, Kort JJ, Schaubel DE, Alloway RR, Durand CM, Fontana RJ, Brown RS Jr, Friedewald JJ, Prenner S, Landis JR, Fernando M, Phillips CC, Woodle ES, Rike-Shields A, Sherman KE, Elias N, Williams WW, Gustafson JL, Desai NM, Barnaba B, Norman SP, Doshi M, Sultan ST, Aull MJ, Levitsky J, Belshe DS, Chung RT, Reese PP. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. J Am Soc Nephrol 2020;31:2678-87. [PMID: 32843477 DOI: 10.1681/ASN.2020050686] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
5 El Helou G, Jay C, Nunez M. Hepatitis C virus and kidney transplantation: Recent trends and paradigm shifts. Transplantation Reviews 2022;36:100677. [DOI: 10.1016/j.trre.2021.100677] [Reference Citation Analysis]
6 Logan C, Yumul I, Cepeda J, Pretorius V, Adler E, Aslam S, Martin NK. Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients. Am J Transplant 2021;21:657-68. [PMID: 32777173 DOI: 10.1111/ajt.16245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Bethea E, Arvind A, Gustafson J, Andersson K, Pratt D, Bhan I, Thiim M, Corey K, Bloom P, Markmann J, Yeh H, Elias N, Kimura S, Dageforde LA, Cuenca A, Kawai T, Safa K, Williams W, Gilligan H, Sise M, Fishman J, Kotton C, Kim A, Rogers CC, Shao S, Cote M, Irwin L, Myoung P, Chung RT. Immediate administration of antiviral therapy after transplantation of hepatitis C-infected livers into uninfected recipients: Implications for therapeutic planning. Am J Transplant. 2020;20:1619-1628. [PMID: 31887236 DOI: 10.1111/ajt.15768] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
8 La Hoz RM, Sandıkçı B, Ariyamuthu VK, Tanriover B. Short-term outcomes of deceased donor renal transplants of HCV uninfected recipients from HCV seropositive nonviremic donors and viremic donors in the era of direct-acting antivirals. Am J Transplant 2019;19:3058-70. [PMID: 31207073 DOI: 10.1111/ajt.15496] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
9 Chan S, Isbel NM, Hawley CM, Campbell SB, Campbell KL, Morrison M, Francis RS, Playford EG, Johnson DW. Infectious Complications Following Kidney Transplantation-A Focus on Hepatitis C Infection, Cytomegalovirus Infection and Novel Developments in the Gut Microbiota. Medicina (Kaunas) 2019;55:E672. [PMID: 31590269 DOI: 10.3390/medicina55100672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Feld JJ, Cypel M, Kumar D, Dahari H, Pinto Ribeiro RV, Marks N, Kamkar N, Bahinskaya I, Onofrio FQ, Zahoor MA, Cerrochi O, Tinckam K, Kim SJ, Schiff J, Reichman TW, McDonald M, Alba C, Waddell TK, Sapisochin G, Selzner M, Keshavjee S, Janssen HLA, Hansen BE, Singer LG, Humar A. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020;5:649-657. [PMID: 32389183 DOI: 10.1016/s2468-1253(20)30081-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
11 Abara WE, Collier MG, Moorman A, Bixler D, Jones J, Annambhotla P, Bowman J, Levi ME, Brooks JT, Basavaraju SV. Characteristics of Deceased Solid Organ Donors and Screening Results for Hepatitis B, C, and Human Immunodeficiency Viruses - United States, 2010-2017. MMWR Morb Mortal Wkly Rep 2019;68:61-6. [PMID: 30677008 DOI: 10.15585/mmwr.mm6803a2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
12 Franco A, Moreso F, Sancho A, Esforzado N, Paul J, Llorente S, Crespo M, Guirado L, Melilli E, Roncero FG. Protocol for Optimizing the Use of Kidneys From Donors With Seropositivity for Hepatitis C Virus in Seronegative Recipients. Transplant Proc 2021;53:2655-8. [PMID: 34657711 DOI: 10.1016/j.transproceed.2021.09.013] [Reference Citation Analysis]
13 Park H, Jung ES, Lee MH, Lee JM. Organ Donation from Donors with Hepatitis B or C in South Korea: A 2013-2017 Nationwide Data Analysis. Ann Transplant 2021;26:e928947. [PMID: 33927178 DOI: 10.12659/AOT.928947] [Reference Citation Analysis]
14 Abaalkhail F, Al-hamoudi W, Altraif I, Mohamed H, Aleid H, Broering D, Alqahtani S. Treatment with Grazoprevir/Elbasvir in Post-kidney Transplant Patients with Hepatitis C Virus Genotype 4 Infection. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon.110260] [Reference Citation Analysis]
15 Pagan J, Ladino M, Roth D. Kidney Transplantation From a Hepatitis C Virus-Infected Donor Into an Uninfected Recipient: Ready for Prime Time? Kidney Int Rep 2020;5:386-8. [PMID: 32281985 DOI: 10.1016/j.ekir.2020.02.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Concepcion BP, Binari LA, Schaefer H, Rega S, Feurer I, Shawar S, Naik R, Hickman L, Walker J, Kapp M, Birdwell KA, Langone A, Helderman JH, Ann Sarrell B, Kochar G, Dubray B, Smith K, O'Dell H, DeMers A, Shelton P, Perri R, Shaffer D, Forbes RC. Kidney Transplantation From Hepatitis C Viremic Deceased Donors to Aviremic Recipients in a Real-world Setting. Transplant Direct 2021;7:e761. [PMID: 34514116 DOI: 10.1097/TXD.0000000000001217] [Reference Citation Analysis]
17 Durand CM, Chattergoon MA. Bypassing the bottleneck: intentional hepatitis C transmission with organ transplant. J Clin Invest 2019;129:3038-40. [PMID: 31232703 DOI: 10.1172/JCI129982] [Reference Citation Analysis]
18 Potluri VS, Goldberg DS, Mohan S, Bloom RD, Sawinski D, Abt PL, Blumberg EA, Parikh CR, Sharpe J, Reddy KR, Molnar MZ, Sise M, Reese PP. National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys. J Am Soc Nephrol. 2019;30:1939-1951. [PMID: 31515244 DOI: 10.1681/asn.2019050462] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
19 Yu K, King K, Husain SA, Dube GK, Stevens JS, Ratner LE, Cooper M, Parikh CR, Mohan S. Kidney nonprocurement in solid organ donors in the United States. Am J Transplant 2020;20:3413-25. [PMID: 32342627 DOI: 10.1111/ajt.15952] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Mazur RD, Abt PL, Blumberg EA, Bloom RD, Reddy KR, Reese PP, Goldberg DS. Characterization of early hepatic injury in HCV-negative recipients of HCV-infected kidneys. Clin Transplant 2019;33:e13494. [PMID: 30779252 DOI: 10.1111/ctr.13494] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Rajasekaran A, Franco RA, Overton ET, McGuire BM, Towns GC, Locke JE, Sawinski DL, Bell EK. Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. Kidney Int Rep 2021;6:1788-98. [PMID: 34307975 DOI: 10.1016/j.ekir.2021.04.015] [Reference Citation Analysis]
22 Griffiths P, Haque T, Marshall A. Management of HCV peri-transplant recapitulates management of CMV. Rev Med Virol 2019;29:e2091. [PMID: 31709643 DOI: 10.1002/rmv.2091] [Reference Citation Analysis]
23 Parlati L, Pol S. HCV-infected dialysis patients: History is changing. Clin Res Hepatol Gastroenterol 2019;43:225-7. [PMID: 30616879 DOI: 10.1016/j.clinre.2018.12.006] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Sise ME, Strohbehn IA, Bethea E, Gustafson JL, Chung RT. Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors. Curr Opin Organ Transplant 2019;24:351-7. [PMID: 31090648 DOI: 10.1097/MOT.0000000000000651] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Holscher CM, Bowring MG, Haugen CE, Zhou S, Massie AB, Gentry SE, Segev DL, Garonzik Wang JM. National Variation in Increased Infectious Risk Kidney Offer Acceptance. Transplantation 2019;103:2157-63. [PMID: 31343577 DOI: 10.1097/TP.0000000000002631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Solli P, Dolci G, Ranieri VM. The new frontier of hepatitis C virus (HCV)-mismatched heart and lung transplantation. Ann Transl Med 2019;7:S279. [PMID: 32015998 DOI: 10.21037/atm.2019.11.123] [Reference Citation Analysis]
27 Cohen-Bucay A, Gordon CE, Francis JM. Non-immunological complications following kidney transplantation. F1000Res. 2019;8. [PMID: 30828430 DOI: 10.12688/f1000research.16627.1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
28 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
29 Khairallah P, Kudose S, Morris HK, Ratner LE, Mohan S, Radhakrishnan J, Chang JH. Reversal of Donor Hepatitis C Virus-Related Mesangial Proliferative GN in a Kidney Transplant Recipient. J Am Soc Nephrol 2020;31:2246-9. [PMID: 32938647 DOI: 10.1681/ASN.2020060820] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Yuan Q, Cui H, Leya GA, Hong S, Roth EM, Sise ME, Bethea ED, Yeh H, Williams WW, Elias N. Temporal trends and impact of willingness to accept organs from donors with hepatitis C virus. Transpl Int 2021;34:2562-9. [PMID: 34726801 DOI: 10.1111/tri.14152] [Reference Citation Analysis]
31 Callaghan CJ, Marks SD. Utilisation of kidneys from deceased donors at increased risk of infectious disease transmission: a step in the right direction. Pediatr Nephrol 2020;35:177-9. [PMID: 31667621 DOI: 10.1007/s00467-019-04380-x] [Reference Citation Analysis]
32 Kulkarni HS, Korenblat KM, Kreisel D. Expanding the donor pool for lung transplantation using HCV-positive donors. J Thorac Dis 2019;11:S1942-6. [PMID: 31632793 DOI: 10.21037/jtd.2019.08.27] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Bowring MG, Shaffer AA, Massie AB, Cameron A, Desai N, Sulkowski M, Garonzik-Wang J, Segev DL. Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States. Am J Transplant 2019;19:2329-41. [PMID: 30861279 DOI: 10.1111/ajt.15355] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
34 Yazawa M, Fülöp T, Cseprekal O, Talwar M, Balaraman V, Bhalla A, Azhar A, Kovesdy CP, Eason JD, Molnar MZ. The incidence of cytomegalovirus infection after deceased-donor kidney transplantation from hepatitis-C antibody positive donors to hepatitis-C antibody negative recipients. Ren Fail 2020;42:1083-92. [PMID: 33100098 DOI: 10.1080/0886022X.2020.1835675] [Reference Citation Analysis]
35 Shetty A, Buch A, Saab S. Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients. Dig Dis Sci 2019;64:1110-8. [PMID: 30560331 DOI: 10.1007/s10620-018-5404-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
36 Fleetwood VA, Maher K, Satish S, Varma CR, Nazzal M, Randall H, Al-Adra DP, Caliskan Y, Bastani B, Rub FAA, Lentine KL. Clinician and patient attitudes toward use of organs from hepatitis C viremic donors and their impact on acceptance: A contemporary review. Clin Transplant 2021;:e14519. [PMID: 34672392 DOI: 10.1111/ctr.14519] [Reference Citation Analysis]
37 Jones JM, Kracalik I, Levi ME, Bowman JS 3rd, Berger JJ, Bixler D, Buchacz K, Moorman A, Brooks JT, Basavaraju SV. Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection - U.S. Public Health Service Guideline, 2020. MMWR Recomm Rep 2020;69:1-16. [PMID: 32584804 DOI: 10.15585/mmwr.rr6904a1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
38 Axelrod DA, Lentine KL, Balakrishnan R, Chang SH, Alhamad T, Xiao H, Kasiske BL, Bloom RD, Schnitzler MA. Financial Evaluation of Kidney Transplant With Hepatitis C Viremic Donors to Uninfected Recipients. Transplant Direct 2020;6:e627. [PMID: 33204825 DOI: 10.1097/TXD.0000000000001056] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Edmonds C, Carver A, DeClercq J, Choi L, Peter M, Schlendorf K, Perri R, Forbes RC, Concepcion BP. Access to hepatitis C direct-acting antiviral therapy in hepatitis C-positive donor to hepatitis C-negative recipient solid-organ transplantation in a real-world setting. Am J Surg 2021:S0002-9610(21)00528-6. [PMID: 34548142 DOI: 10.1016/j.amjsurg.2021.09.005] [Reference Citation Analysis]
40 Zahid MN, Wang S, Learn GH, Abt PL, Blumberg EA, Reese PP, Goldberg DS, Shaw GM, Bar KJ. High multiplicity infection following transplantation of hepatitis C virus-positive organs. J Clin Invest 2019;129:3134-9. [PMID: 31112523 DOI: 10.1172/JCI127203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
41 Verna EC, Schluger A, Brown RS Jr. Opioid epidemic and liver disease. JHEP Rep 2019;1:240-55. [PMID: 32039374 DOI: 10.1016/j.jhepr.2019.06.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
42 Karpel HC, Ali NM, Lawson N, Tatapudi VS, Friedlander R, Philogene MC, Montgomery RA, Lonze BE. Successful A2 to B Deceased Donor Kidney Transplant after Desensitization for High-Strength Non-HLA Antibody Made Possible by Utilizing a Hepatitis C Positive Donor. Case Rep Transplant 2020;2020:3591274. [PMID: 32231847 DOI: 10.1155/2020/3591274] [Reference Citation Analysis]
43 Van Pilsum Rasmussen SE, Seaman S, Brown D, Desai N, Sulkowski M, Segev DL, Durand CM, Sugarman J. Patient's Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site. AJOB Empir Bioeth 2020;11:40-52. [PMID: 31618112 DOI: 10.1080/23294515.2019.1670277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
44 Ariyamuthu VK, Tanriover B. Optimizing Utilization of Kidneys from Hepatitis C-Positive Kidney Donors. Clin J Am Soc Nephrol 2021;16:188-90. [PMID: 33451991 DOI: 10.2215/CJN.19431220] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Fabrizi F, Cerutti R, Alfieri CM, Messa P. Updated View on Kidney Transplant from HCV-Infected Donors and DAAs. Pharmaceutics 2021;13:496. [PMID: 33917382 DOI: 10.3390/pharmaceutics13040496] [Reference Citation Analysis]
46 Edwards GC, Shipe ME, Smith L, Gamble C, Shaffer D, Concepcion BP, Forbes R. Exploring patient willingness to accept hepatitis C-infected kidneys for transplantation. BMC Nephrol 2020;21:473. [PMID: 33172408 DOI: 10.1186/s12882-020-02114-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Stewart ZA, Stern J, Ali NM, Kalia HS, Khalil K, Jonchhe S, Weldon EP, Dieter RA, Lewis TC, Funches N, Crosby S, Seow M, Berger JC, Dagher NN, Gelb BE, Watkins AC, Moazami N, Smith DE, Kon ZN, Chang SH, Reyentovich A, Angel LF, Montgomery RA, Lonze BE. Clinical and Financial Implications of 2 Treatment Strategies for Donor-derived Hepatitis C Infections. Transplant Direct 2021;7:e762. [PMID: 34514117 DOI: 10.1097/TXD.0000000000001222] [Reference Citation Analysis]
48 Duerr M, Liefeldt L, Friedersdorff F, Choi M, Öllinger R, Hofmann J, Budde K, Schrezenmeier E, Halleck F. Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients. J Clin Med 2020;10:E89. [PMID: 33383877 DOI: 10.3390/jcm10010089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Agbim U, Cseprekal O, Yazawa M, Talwar M, Balaraman V, Bhalla A, Podila PSB, Maliakkal B, Nair S, Eason JD, Molnar MZ. Factors associated with hepatitis C antibody seroconversion after transplantation of kidneys from hepatitis C infected donors to hepatitis C naïve recipients. Ren Fail 2020;42:767-75. [PMID: 32729359 DOI: 10.1080/0886022X.2020.1798784] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Mailly L, Wrensch F, Heydmann L, Fauvelle C, Brignon N, Zeisel MB, Pessaux P, Keck ZY, Schuster C, Fuerst TR, Foung SKH, Baumert TF. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection. Antiviral Res 2019;162:136-41. [PMID: 30599173 DOI: 10.1016/j.antiviral.2018.12.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
51 Reddy YNV, Reddy KP, Sise ME. HCV-Infected Deceased Donor Kidney Transplantation-Time to Take Up the Offer. Am J Kidney Dis 2020;75:827-9. [PMID: 32317120 DOI: 10.1053/j.ajkd.2020.01.010] [Reference Citation Analysis]
52 Cox A, Sulkowski M, Sugarman J. Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine. Clin Infect Dis 2020;71:2986-90. [PMID: 32442262 DOI: 10.1093/cid/ciaa640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Lafargue MC, Caliskan Y, Lentine KL, Riella LV. Opioids and Kidney Transplantation. Semin Nephrol 2021;41:42-53. [PMID: 33896473 DOI: 10.1016/j.semnephrol.2021.02.005] [Reference Citation Analysis]
54 Sise ME, Wojciechowski D, Chute DF, Gustafson J, Chung RT, Williams WW, Elias N. Process of selecting and educating HCV-uninfected kidney waiting-list candidates for HCV-infected kidney transplantation. Artif Organs 2019;43:913-20. [PMID: 31001828 DOI: 10.1111/aor.13473] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Sise ME, Strohbehn IA, Chute DF, Gustafson J, Van Deerlin VM, Smith JR, Gentile C, Wojciechowski D, Williams WW, Elias N, Chung RT. Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation. Kidney Int Rep 2020;5:459-67. [PMID: 32280841 DOI: 10.1016/j.ekir.2020.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
56 Lentine KL, Peipert JD, Alhamad T, Caliskan Y, Concepcion BP, Forbes R, Schnitzler M, Chang SH, Cooper M, Bloom RD, Mannon RB, Axelrod DA. Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers. Kidney360 2020;1:1291-9. [PMID: 33251523 DOI: 10.34067/KID.0004592020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]